SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference,
Evercore ISI Group Initiates Coverage of SpringWorks Therapeutics (SWTX) with Outperform Recommendation
Fintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) with a Outperform recommendation. Analyst Price Forecast Suggests 84.32% Upside As of October 22,
Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference
Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of CAR-T cells, today announced that members of management will participate in a fireside chat and 1x1 investor meetings at the 7th Annual Evercore ISI HealthCONx Conference,
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer.
pharmaphorum2d
ESMO: SpringWorks notches up a win in desmoid tumours
Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported phase 3 data at ESMO that sets up regulatory filings for its lead drug nirogacestat ...
SpringWorks Therapeutics Inc. (SWTX): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...
Business Insider18d
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial ...
pharmaphorum2d
SpringWorks spins out of Pfizer on rare disease mission
SpringWorks will be led by a team of industry veterans including executive chairman Daniel Lynch, with more than 25 years of industry experience, and vice president of clinical R&D Mary Smith, who ...
Seeking Alpha26d
SpringWorks Therapeutics Merits A Speculative Buy
When we last visited SpringWorks, the company was trying to get its primary drug candidate nirogacestat through the FDA approval process. Nirogacestat is an oral small-molecule gamma-secretase ...
Nasdaq17d
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had ...
Vertex leads J.P. Morgan's top biotech picks list for 2025
J.P.  Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), ...
Seeking Alpha5d
Finding Winners In Biotech, Probably The Riskiest Sector
Key stocks to watch include Tarsus Pharmaceuticals and SpringWorks Therapeutics, both showing strong potential based on ...